Home › Compound Library › TB-500
Structural repair
TB-500 and Thymosin Beta-4: What They Are, How They Differ, and What the Research Shows
The short answer
TB-500 is a lab-made fragment of thymosin beta-4, a natural 43-amino-acid peptide found in high amounts in platelets and wound fluid. It works on actin, the scaffolding cells use to move into a wound, and in animal studies supports tendon, muscle and wound repair. The fragment itself has no published human trials, and it is banned in sport.
Questions people ask about TB-500
TB-500 at a glance
| Also called | Thymosin beta-4 fragment; TB4 fragment (17–23) |
|---|---|
| What it is | Synthetic fragment of thymosin beta-4 containing its actin-binding region |
| Main system | Tissue repair, cell migration, blood-vessel growth |
| Evidence level | Investigational: animal data; limited human data for full-length thymosin beta-4 only |
| FDA status (Sept 2026) | Not approved. FDA advisory panel voted 8–6 in July 2026 to recommend it for pharmacy compounding; not yet final |
| Anti-doping | Thymosin beta-4 and derivatives such as TB-500 are prohibited under WADA rules |
What is TB-500?
Thymosin beta-4 (Tβ4) is a natural peptide of 43 amino acids, concentrated in platelets, macrophages and wound fluid, the places repair happens (Regenerative Resilience, p. 111). TB-500 is a short synthetic fragment of it, built around the region that binds actin (Targeted Peptide Systems, p. 198).
In practice the two are discussed together, and many products marketed as “thymosin beta-4” are actually the fragment. They are not identical.
Is TB-500 the same as thymosin beta-4?
No. Full-length thymosin beta-4 is the parent molecule, with broader effects including more immune modulation. TB-500 is the fragment that carries its actin-binding and cell-migration activity in a smaller, cheaper-to-make form (Regenerative Resilience, pp. 113–115). The books treat them as partly redundant, which is why a repair plan would normally use one or the other, not both.
One practical difference matters when reading research: the human trials that exist used full-length thymosin beta-4, not the TB-500 fragment.
How does TB-500 work?
Cells can’t repair a wound without moving into it, and to move they constantly build and break down actin, their internal scaffolding. Thymosin beta-4 is the body’s main regulator of that process (reference 1). Through it, research links thymosin beta-4 and TB-500 to:
- Faster migration of fibroblasts and blood-vessel cells into injured tissue
- New blood-vessel growth through VEGF
- Lower inflammatory signalling and less scar-forming fibrosis in animal models
- Mobilising heart progenitor cells after injury in mice, a widely cited 2007 study in Nature (reference 2)
Unlike growth-hormone-type peptides, it does not directly raise anabolic hormones, which is why the books describe it as combinable with virtually any other category (Regenerative Resilience, p. 114).
Are there human studies on TB-500?
For the TB-500 fragment itself, no published clinical trials. For full-length thymosin beta-4, yes, mainly as eye drops. In a small randomised Phase III trial in neurotrophic keratopathy (a hard-to-heal corneal condition), 0.1% thymosin beta-4 drops showed faster healing and better comfort than placebo (reference 3). A later European Phase 3 trial of the same eye drop missed its primary endpoint.
So the honest picture is solid animal biology, some encouraging human data for the parent molecule in one specific use, and nothing yet for the injectable fragment people usually mean by “TB-500.”
TB-500 side effects and safety
- Animal and early human data for thymosin beta-4 suggest it is generally well tolerated. Long-term human safety data are limited.
- Because it drives cell migration and blood-vessel growth, there is a theoretical concern for anyone with an existing cancer. That is why The Longevity Map calls it “not a compound to use casually or without medical input” (p. 72).
- Products sold as research chemicals are unregulated; purity and sterility aren’t guaranteed.
Is TB-500 legal, FDA approved, or banned in sport?
Not FDA approved. On July 23, 2026 the FDA’s Pharmacy Compounding Advisory Committee voted 8–6, with one abstention, to recommend adding TB-500 to the 503A bulks list for compounding pharmacies. The recommendation is not binding and still needs formal approval (references 4, 5).
Banned in sport. The World Anti-Doping Agency prohibits thymosin beta-4 and its derivatives, naming TB-500 specifically (reference 6).
TB-500 vs BPC-157, and why people take them together
BPC-157 repairs mainly through new blood vessels and nitric oxide signalling. TB-500 repairs through actin and cell movement. Because the pathways are distinct, our Protocol Builder treats the pair as complementary rather than overlapping, and both appear in the GLOW and KLOW blends with GHK-Cu.
One difference often mentioned: TB-500 is described as acting systemically, travelling through the body, while BPC-157 research includes both systemic and near-the-injury use (Regenerative Resilience, pp. 109, 114).
TB-500: frequently asked questions
What is TB-500?
TB-500 is a synthetic fragment of thymosin beta-4, a natural repair peptide. It works on actin and cell movement and is studied for tendon, muscle and wound repair.
Is TB-500 the same as thymosin beta-4?
No. Thymosin beta-4 is the full 43-amino-acid natural peptide; TB-500 is a short synthetic fragment containing its actin-binding region. They overlap but aren’t identical.
What is the difference between TB-500 and BPC-157?
TB-500 works through actin and cell migration; BPC-157 works mainly through blood-vessel growth and nitric oxide signalling. Different pathways are why they are often combined.
Is TB-500 FDA approved?
No. In July 2026 an FDA advisory committee voted 8–6 to recommend allowing it in pharmacy compounding, but that vote is not binding and is not a drug approval.
Is TB-500 banned by WADA?
Yes. The WADA Prohibited List bans thymosin beta-4 and its derivatives and names TB-500 specifically.
Are there human studies on TB-500?
Not for the TB-500 fragment. Full-length thymosin beta-4 has been tested in humans as eye drops, with mixed Phase 3 results.
Is TB-500 safe?
Early data suggest it is generally well tolerated, but long-term human safety is unknown. Because it promotes cell migration and blood-vessel growth, people with a cancer history should not use it without medical input.
Is TB-500 systemic or local?
Research describes TB-500 as distributing systemically through the body rather than acting only where it is given.
Why take TB-500 with BPC-157?
They support repair through different pathways, cell movement for TB-500 and blood supply for BPC-157, so combining them covers more of the healing process.
Does TB-500 cause cancer?
There is no human evidence that it does. The concern is theoretical: it promotes processes like cell migration and blood-vessel growth that could matter if a cancer already exists.
Where TB-500 appears in our books
This page is the plain-language overview. The books go further: mechanism detail, evidence tiers, how TB-500 fits a full protocol, and the cautions that go with it. Page numbers refer to the print editions.
Related compounds
See how TB-500 fits a protocol
The free Protocol Builder maps the pathways a compound works on and shows what complements it for your goal, built from the same database as this library.
Open the Protocol BuilderSee the book seriesReferences
- Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012;12(1):37–51. View sourceCited in Regenerative Resilience (p. 348)
- Smart N, Risebro CA, Melville AA, et al. Thymosin beta4 induces adult epicardial progenitor mobilization and neovascularization. Nature. 2007;445(7124):177–182. View sourceCited in Targeted Peptide Systems (p. 349), The Cognitive Advantage (p. 409), Metabolic Precision (p. 356) and Regenerative Resilience (p. 348)
- Sosne G, Kleinman HK, Springs C, et al. 0.1% RGN-259 (Thymosin β4) Ophthalmic Solution Promotes Healing and Improves Comfort in Neurotrophic Keratopathy Patients in a Randomized, Placebo-Controlled, Double-Masked Phase III Clinical Trial. Int J Mol Sci. 2022;24(1):554. View source
- U.S. Food and Drug Administration. July 23–24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. View source
- National Community Pharmacists Association. FDA advisory committee nominates six peptides for pharmacies to compound. July 31, 2026. View source
- World Anti-Doping Agency. The 2026 Prohibited List. View source
How this page is maintained. Regulatory status and trial results change. We review this page against current sources and update it as new information becomes available; the date at the top shows the last review.
Educational information only, not medical advice. TB-500 is discussed here for education. Nothing on this page is a recommendation to use it or a dosing guide. Talk to a qualified clinician before starting, stopping or combining any compound.